Navigation Links
Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
Date:1/17/2008

KENILWORTH, N.J., Jan. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) announced that Nippon Organon K.K., now part of Schering-Plough, has filed a New Drug Application with the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking marketing approval for its novel selective relaxant binding agent (SRBA), sugammadex.

Sugammadex is specifically designed to rapidly reverse to rapidly reverse the effects of certain muscle relaxants, rocuronium bromide (marketed in the U.S. as ZEMURON(R) and in Japan as ESLAX(R)), as well as vecuronium bromide (marketed in Japan as MUSCULAX(R)). Muscle relaxants are used as part of general anesthesia during surgical procedures.

The company announced on January 2, 2008, that the U.S. Food and Drug Administration (FDA) has assigned priority review status to the New Drug Application (NDA) filing for sugammadex. Additionally, the Marketing Authorization Application for sugammadex was accepted for review by the European Medicines Agency (EMEA) in July 2007.

Schering-Plough acquired sugammadex through its combination with Organon BioSciences on November 19, 2007.

About Sugammadex

Sugammadex is a novel selective relaxant binding agent (SRBA) under development by Organon, a part of Schering-Plough Corporation. Sugammadex was designed to reverse the effects of rocuronium bromide or vecuronium bromide, muscle relaxants commonly used during surgeries that require profound muscle relaxation. Anesthesiologists use muscle relaxation to improve surgical conditions, to facilitate intubation and mechanical ventilation, and to reduce the chance of complications.

In clinical trials to date, sugammadex has demonstrated the ability to rapidly reverse shallow an
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... ... global failure analysis market is expected to reach $7,147.0 million by 2020, at a ... at the highest CAGR of 8.46%; its growth is expected to be driven by ... for root cause analysis of failure. The market based on the geographic regions has ...
(Date:7/3/2015)... 3, 2015 Forskere ... 2015 på  http://www.openinnovationinscience.at om efteruddannelsesprogrammet "Lab ... sted i Wien .  ... internationale forskere og videnskabsmænd foretaget af Ludwig ... udfordringer for sundhedsvidenskaben manglen på incitamenter til ...
(Date:7/2/2015)... , July 2, 2015 Amici ... Bio-tech procurement company Amici Procurement has chosen Microsoft Cloud ... it move to Office 365.      (Logo: ... small to medium-sized companies in the bio-tech sector with ... of the purchasing cycle to help them obtain best ...
(Date:7/1/2015)... and PARIS , ... AgBiome, and Genective, key developer of biotech crops, ... discovery of new generations of insect control traits. ... control to counter the realities of advancing insect ... aligning AgBiome,s unique insect control technology with Genective,s ...
Breaking Biology Technology:Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Biotech Procurement Company Moves to Office 365 with iomart 2AgBiome and Genective collaborate to create novel insect-resistant crops 2
... specialist and a healthcare economist both say that the ... drug to market does not hold up to close ... (GEN). The researchers emphasize that available cost data cannot ... internal and external sources of variability, according to the ...
... KALAMAZOO, Mich., July 6, 2011 Metabolic Solutions Development ... novel molecular targets to treat metabolic diseases, announced today ... Alzheimer,s Drug Discovery Foundation (ADDF) to conduct a pilot ... the treatment of metabolic diseases associated with altered mitochondrial ...
... Inc., a privately held company developing and commercializing novel ... for new and existing therapeutics, announced today that effective ... been elected as chairman for the company,s board of ... pathologist with more than 20 years experience in the ...
Cached Biology Technology:GEN point of view article questions reported costs of drug R&D 2Metabolic Solutions Development Company Receives $773,000 From the Alzheimer's Drug Discovery Foundation to Fund Phase 2a Trial 2Metabolic Solutions Development Company Receives $773,000 From the Alzheimer's Drug Discovery Foundation to Fund Phase 2a Trial 3Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Company's Board of Directors 2Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Company's Board of Directors 3
(Date:6/17/2015)... , June 17, 2015 QIAGEN ... launched new Investigator ® STR assay kits for analysis ... United States . The new genetic fingerprint kits provide ... (short tandem repeats or STRs) for DNA matching. They incorporate ... of DNA in each sample, a novel QIAGEN technology that ...
(Date:6/16/2015)... , June 16, 2015  With the increasing ... security remains a top concern. The recent compromise of ... the need for strong authentication within government agencies. ... a biometric one-time password (OTP) authenticator, has been submitted ... (FIPS) 140-2 Level 3 validation for tamper proofing. ...
(Date:6/15/2015)... -- A new report [ 1 ... US consumers using mobile banking applications want their mobile devices ... voiceprint, instead of having to prove who they are with ... Identity   -   The Fusion of Financial Services, Mobile ... primary channel used by Gen X and Gen Y to ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... University of Kansas researchers have found that the infants ... fatty acid DHA during pregnancy weighed more at birth and ... born before 34 weeks gestation than infants of mothers who ... for using the dietary supplement during pregnancy. Susan CarlsonThe ...
... what may be a major factor behind the increased ... in vitro fertilization (IVF). Two papers published in ... hypothesis that extremely high estrogen levels at the time ... be born small for their gestational age and the ...
... of Nottingham has been used in a breakthrough study ... fully functioning fetal heart. The abdominal fetal ECG ... of Electrical and Electronic Engineering and on commercial sale ... company Monica Healthcare Ltd, has been used to observe ...
Cached Biology News:Prenatal DHA reduces early preterm birth, low birth weight 2Extremely high estrogen levels may underlie complications of single-birth IVF pregnancies 2Extremely high estrogen levels may underlie complications of single-birth IVF pregnancies 3Nottingham technology in heart development breakthrough 2Nottingham technology in heart development breakthrough 3Nottingham technology in heart development breakthrough 4